In the trial, we determined the effects of the clinical efficacy, blood lipid level, endothelial injury marker index (NO), inflammatory factor index (IL-1β and TNF-α), oxidative stress indicators (MDA and SOD), and the PI3K-AKt pathway and its downstream proteins (PI3k, AKt, NF-κB, eNOS, and GSK-3β) in patients with CHD with BSS. This evidence concerns the gene SOD1 and coronary artery disorder.